{
    "ticker": "DRMA",
    "name": "Dermata Therapeutics, Inc.",
    "description": "Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and dermatological diseases. Founded in 2015, Dermata is committed to addressing significant unmet medical needs in skin conditions such as psoriasis and atopic dermatitis through its proprietary technology platform. The company\u2019s lead product candidate, DMT310, is a topical treatment designed to provide safe, effective, and convenient relief for patients suffering from these chronic skin disorders. Dermata's research and development are driven by a passionate team of scientists and industry veterans who leverage advanced drug delivery systems to enhance therapeutic outcomes. With a focus on patient-centric solutions, Dermata aims to improve the quality of life for individuals affected by these conditions. The company's mission is to bring innovative dermatological therapies to market that can change the landscape of treatment and ultimately benefit patients globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2015",
    "website": "https://www.dermatatx.com",
    "ceo": "Derek Chalmers",
    "social_media": {
        "twitter": "https://twitter.com/DermataTx",
        "linkedin": "https://www.linkedin.com/company/dermata-therapeutics/"
    },
    "investor_relations": "https://investors.dermatatx.com",
    "key_executives": [
        {
            "name": "Derek Chalmers",
            "position": "CEO"
        },
        {
            "name": "Sharon G. R. Levy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "DMT310"
            ]
        }
    ],
    "seo": {
        "meta_title": "Dermata Therapeutics, Inc. | Innovative Dermatological Therapies",
        "meta_description": "Explore Dermata Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune and dermatological diseases.",
        "keywords": [
            "Dermata Therapeutics",
            "DMT310",
            "Dermatology",
            "Biotechnology",
            "Pharmaceuticals",
            "Psoriasis",
            "Atopic Dermatitis"
        ]
    },
    "faq": [
        {
            "question": "What does Dermata Therapeutics focus on?",
            "answer": "Dermata Therapeutics focuses on developing innovative therapies for autoimmune and dermatological diseases."
        },
        {
            "question": "What is DMT310?",
            "answer": "DMT310 is Dermata's lead product candidate, a topical treatment for chronic skin conditions like psoriasis."
        },
        {
            "question": "Where is Dermata Therapeutics headquartered?",
            "answer": "Dermata Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Dermata Therapeutics founded?",
            "answer": "Dermata Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "REGN",
        "ABBV"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "GILD"
    ]
}